CLORAZEPATE DIPOTASSIUM (clorazepate dipotassium) by PharmaIN is clinical pharmacology pharmacologically, clorazepate dipotassium has the characteristics of the benzodiazepines. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications. First approved in 2022.
Drug data last refreshed 21h ago
CLINICAL PHARMACOLOGY Pharmacologically, clorazepate dipotassium has the characteristics of the benzodiazepines. It has depressant effects on the central nervous system. The primary metabolite, nordiazepam, quickly appears in the blood stream. The serum half-life is about 2 days. The drug is…
Worked on CLORAZEPATE DIPOTASSIUM at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.